DSM Firmenich (OTCPK:DSFI.Y) Update / briefing Transcript

Summary of Conference Call Company and Industry - Company: dsm-firmenich - Industry: Nutrition, Health, and Beauty Key Points and Arguments Divestment Announcement - dsm-firmenich announced the divestment of Animal Nutrition & Health (ANH) to CVC Capital Partners for a total enterprise value of $2.2 billion. The proceeds at closing are expected to be $1.2 billion, with a 20% retained stake in the company and an earn-out possibility of $0.5 billion [2][3] Transaction Structure - The transaction will split ANH into two standalone entities: one focused on solutions and the other on essential products, primarily vitamins. The target completion date for this separation is around the end of 2026 [3][4] Financial Metrics - The valuation of $2.2 billion represents approximately 7x EV over Adjusted EBITDA multiple. The earlier announced feed enzyme sale last year had a 10x multiple, bringing the total to $3.7 billion [3][12] Capital Allocation - dsm-firmenich will maintain a stable dividend of €2.50 and initiate a share buyback program of $500 million in addition to a previously announced €1 billion buyback by 2025 [4][13] Future Financial Reporting - The company plans to launch restated financials reflecting the consumer part of the business post-ANH divestment. Full-year results are expected on February 12, 2026 [5][10] Impairment and Financial Adjustments - The transaction resulted in a non-cash impairment of approximately €1.9 billion, primarily linked to goodwill and intangibles from the merger. This impairment will be processed in the 2025 full-year results [11][12] Earnings and Dividend Policy - The dividend policy has been adjusted to a stable to preferably rising approach, moving away from the previous distribution range of 40%-60% of earnings. The company aims to return to a comfortable coverage range for dividends within a relatively short period [31][32] Supply Agreement - A long-term vitamin supply agreement has been secured under favorable conditions, which will help mitigate volatility in the vitamin market. The pricing structure is more aligned with a cost-plus model [40][41] Separation Costs and Financial Health - Expected separation costs are around €150 million, which will not be included in the net cash proceeds of €600 million. The company has plans to mitigate stranded costs associated with the separation [79][80] Strategic Focus - The divestment allows dsm-firmenich to focus on its core consumer business, entering what is termed the "accelerate phase." The company aims to grow its existing business and deliver on midterm targets of 5%-7% growth [95][96] Future Outlook - The company is committed to its midterm strategic targets and will provide further insights during the investor event scheduled for March 12, 2026 [91][92] Additional Important Information - CVC Capital Partners will contribute a few hundred million euros to ensure sufficient liquidity for both entities post-transaction [43] - The separation of the two companies will allow for independent growth paths, with no requirement to exit the retained stake in a combined manner [25][39]